Lung cancer (Amsterdam, Netherlands) 2015-12
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
ABSTRACT
Human epidermal growth factor 2 (HER2, ERBB2) mutations in lung cancers are oncogenic drivers that respond to HER2 targeted therapies. Little is known about the sensitivity of subtypes of HER2 mutant lung cancers to targeted agents. We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib. We demonstrate that afatinib has activity in patients with HER2 mutant lung cancers with exon 20 YVMA insertions, the most common variant.
Related Questions
In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?
New answer by Medical Oncologist at Perelman School of Medicine at the University of Pennsylvania (December 12, 2019)
Very erudite discussions by both @Karen L. Reckamp and @Balazs Halmos. I've very little to add. I just want to remind readers that this patient would have been eligible t...